← All diseases Cancer

Anaplastic thyroid carcinoma

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest level of evidence only (20)Meta-analysis (9)Treatment guideline (3)Systematic review (6)Phase 3 study (2)Clinical trial (90)Review article (144)Early study (phase 1 or 2) (46)Case report (144)Laboratory or animal study (46)Commentary or editorial (16)Retracted publication (3) Studies currently recruiting participants only (32)

Filter

Publications and studies (1124)

• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A synergistic drug combination that aids our battle against anaplastic thyroid carcinoma: a case report and discussion. (2026/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The shifting paradigm of programmed cell death ligand 1 (PD-L1) in anaplastic thyroid carcinoma: from pathology to clinical practice. (2026/03/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Stereotactic Radiotherapy for Metastatic Anaplastic Thyroid Cancer: A Single-center Experience and Systematic Review. (2026/03/01) ♡
• YTHDF2-mediated stabilization of SREBF1 promotes lipid metabolic reprogramming and ferroptosis-associated radioresistance in anaplastic thyroid carcinoma. (2026/02/28) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Anaplastic thyroid carcinoma with liposarcomatous foci: a novel heterologous differentiation. (2026/02/01) ♡
• WTAP-mediated m6A modification of PRMT1 regulates cuproptosis to promote anaplastic thyroid carcinoma progression. (2026/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Retroelements in thyroid cancer: epigenetic plasticity, dedifferentiation, and therapeutic opportunities. (2026/02/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Intracranial antitumor efficacy of combination treatment with encorafenib plus binimetinib in BRAF V600E-mutated anaplastic thyroid carcinoma. (2026/02/01) ♡
• Diagnostic value of molecular testing for evaluating thyroid nodules greater than 4 centimeters. (2026/02/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. ALK Inhibition Prolongs Survival in a Mouse Model of ALK-Positive Anaplastic Thyroid Cancer. (2026/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Single-cell sequencing reveals the tumor immune microenvironment in thyroid cancer: a narrow review. (2026/01/05) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Efficacy and safety of immunotherapy in anaplastic thyroid carcinoma: a systematic review and meta-analysis. (2026/01/01) ♡
• The Role of External Beam Radiation Therapy in Thyroid Cancer Management: A Scoping Review. (2026/01/01) ♡
• Toward the development of an innovative pharmacological compound employing peptides for EGFR-mediated drug delivery in anaplastic thyroid carcinoma. (2026/01/01) ♡
• Targeting EZH2 reverses thyroid cell dedifferentiation and enhances iodide uptake in anaplastic thyroid cancer. (2026/01/01) ♡
• Type 2 Deiodinase in Cancer-Associated Fibroblasts is Required to Sustain Growth of Poorly and Undifferentiated Thyroid Cancer. (2026/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Thyroid angiosarcoma: a comprehensive review. (2026/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [Anaplastic thyroid carcinoma: Importance of early diagnosis and treatment]. (2026/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Radioiodine refractory thyroid cancer; Bridging multidisciplinary synergy. (2026/01/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer (2026-08-11) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer (2026-08-10) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer (2026-07-29) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations (2026-07-27) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer (2026-07-24) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (2026-07-20) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer (2026-07-07) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer (2026-07-06) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers (2026-06-25) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (2026-06-23) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Study of Avutometinib and Defactinib in People With Thyroid Cancer (2026-06-22) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial (2026-06-22) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (2026-06-17) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer (2026-06-01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (2026-05-27) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (2026-05-22) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer (2026-05-20) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Thyroid Cancer and Sunitinib (2026-05-14) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer (2026-04-17) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) (2026-04-09) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer (2026-04-08) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC (2026-03-23) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. (2026-02-27) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. [177Lu]Lu-AKIR001 First-in-human Study (2026-01-30) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Review of Genomic Drivers of Thyroid Cancer and Their Clinical Implications. (2025/12/30) ♡
• Organoid-based drug screening identifies homoharringtonine as a therapeutic agent for anaplastic thyroid cancer via TFEB-mediated lysosomal dysfunction. (2025/12/29) ♡
• Comprehensive bioinformatics analysis identified and validated KIT as a key gene associated with glutamine metabolism in thyroid carcinoma. (2025/12/26) ♡
• Antiproliferative activity of Moringa oleifera (L.) Lam. and Moringa stenopetala (Bak.) Cufod. leaves extract against selected cancer cells in primary cell culture. (2025/12/23) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity. (2025/12/23) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Impact of comorbidities on treatment management and prognosis in patients with anaplastic thyroid cancer (ATC). (2025/12/23) ♡
• EpCAM activates the ERK-EGR1 signaling axis and promotes TNF-α-induced the progression of anaplastic thyroid cancer. (2025/12/22) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.